Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.53
+5.2%
$1.62
$1.21
$3.44
$59.62M0.4112,055 shs9,081 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$0.45
-2.7%
$0.76
$0.29
$3.53
$68.37M2.245.33 million shs567,540 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$5.12
-2.8%
$4.77
$3.90
$15.00
$66.49M0.52281,476 shs97,979 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$2.70
-0.4%
$2.71
$2.33
$4.96
$16.74M0.418,533 shs12,603 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
+5.17%+7.39%-11.85%+20.08%-9.47%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-2.69%+4.39%+43.39%-82.90%-75.33%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-2.85%+1.99%+23.67%+1.79%-59.24%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-0.37%-1.46%-1.82%-22.64%-16.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.53
+5.2%
$1.62
$1.21
$3.44
$59.62M0.4112,055 shs9,081 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$0.45
-2.7%
$0.76
$0.29
$3.53
$68.37M2.245.33 million shs567,540 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$5.12
-2.8%
$4.77
$3.90
$15.00
$66.49M0.52281,476 shs97,979 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$2.70
-0.4%
$2.71
$2.33
$4.96
$16.74M0.418,533 shs12,603 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
+5.17%+7.39%-11.85%+20.08%-9.47%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-2.69%+4.39%+43.39%-82.90%-75.33%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-2.85%+1.99%+23.67%+1.79%-59.24%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-0.37%-1.46%-1.82%-22.64%-16.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
1.00
SellN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
1.75
Reduce$5.501,118.43% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.00
Hold$5.00-2.34% Downside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest NAII, IMMP, LFVN, and BYSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeBuyHold$5.00
5/4/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeHold (C)Hold (C-)
3/27/2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
Reiterated RatingSell (D+)
3/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
Reiterated RatingHold (C)
3/13/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
DowngradeBuyHold
3/13/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
DowngradeOutperformNeutral$7.00 ➝ $1.00
3/13/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
DowngradeOutperformMarket Perform
2/23/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Initiated CoverageMarket Outperform$10.00
2/17/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Initiated CoverageMarket Outperform$6.00
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.75M35.83$0.12 per share12.76($0.59) per share-2.58
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$6.69M9.94N/AN/A$0.63 per share0.72
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.28$1.07 per share4.79$2.64 per share1.94
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$129.86M0.13N/AN/A$11.07 per share0.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$1.01M-$0.15N/AN/AN/AN/AN/A-12.73%N/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$39.78MN/AN/AN/AN/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.4511.387.31N/A2.94%23.89%12.47%N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$13.57M-$2.04N/AN/AN/A-9.06%-8.60%-3.92%N/A

Latest NAII, IMMP, LFVN, and BYSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q4 2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$0.54-$0.05+$0.49-$0.05$8.77 millionN/A
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
3/25/2026Q4 2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$0.54-$0.05+$0.49-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.183.52%N/A40.00%3 Years
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A

Latest NAII, IMMP, LFVN, and BYSI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.054%6/1/20266/1/20266/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
1.54
1.54
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
2.97
N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.96
1.04
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.13
1.87
0.85

Institutional Ownership

CompanyInstitutional Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%

Insider Ownership

CompanyInsider Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8041.12 million29.07 millionOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021147.37 million142.85 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.62 million9.85 millionOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable

Recent News About These Companies

Natural Alternatives Resolves Credit Agreement Issues

New MarketBeat Followers Over Time

Media Sentiment Over Time

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$1.52 +0.08 (+5.17%)
Closing price 05/14/2026 03:58 PM Eastern
Extended Trading
$1.48 -0.04 (-2.62%)
As of 07:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$0.45 -0.01 (-2.69%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$0.45 0.00 (-0.31%)
As of 09:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$5.12 -0.15 (-2.85%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$5.04 -0.08 (-1.46%)
As of 09:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$2.70 -0.01 (-0.33%)
As of 05/14/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.